Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genome-Based Assessment of Niraparib (ZEJULA) Efficacy in Advanced Solid Tumors with Homologous Recombination Deficiency (GAUSS)
KCT0009041Phase 2Not yet recruiting
- Sponsor
- Amgen
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in Nonhematologic neoplasms, sponsored by Amgen. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0009041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009041.